Article Information
- Received February 9, 2009
- Revision received March 23, 2009
- Accepted March 30, 2009
- First published May 6, 2009.
- Version of record published May 6, 2009.
Author Information
- Maria K. Lehtinen1,2,
- Saara Tegelberg1,
- Hyman Schipper3,
- Haixiang Su3,
- Hillel Zukor3,
- Otto Manninen1,
- Outi Kopra1,
- Tarja Joensuu1,
- Paula Hakala1,
- Azad Bonni2, and
- Anna-Elina Lehesjoki1
- 1Folkhälsan Institute of Genetics, Department of Medical Genetics and Neuroscience Center, University of Helsinki, 00290 Helsinki, Finland,
- 2Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, and
- 3Centre for Neurotranslational Research, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec H3T 1E2, Canada
- Correspondence should be addressed to either of the following at their above addresses: Azad Bonni, azad_bonni{at}hms.harvard.edu; or Anna-Elina Lehesjoki, E-mail: anna-elina.lehesjoki{at}helsinki.fi
Author contributions
Disclosures
- Received February 9, 2009.
- Revision received March 23, 2009.
- Accepted March 30, 2009.
-
This work was supported by a Sigrid Jusélius Fellowship to M.K.L., the Finnish Graduate School of Neuroscience to S.T., National Institutes of Health Grants to A.B. (NS047188 and NS41021), and the Folkhälsan Research Foundation, the Sigrid Jusélius Foundation, and the Academy of Finland (NEURO Research Programme 2006–2009 and Center of Excellence Programme 2006–2011) to A.-E.L. We thank E. Andermann and F. Andermann for helpful discussions and critical reading of this manuscript; A. Liberman, M. Taipale, and P. Uusen for technical assistance; A. Baici for the human Cathepsin B-GFP plasmid; K. Brix for the rat Cathepsin B–GFP plasmid; G. Suske for the Sp1 plasmid; N. Perkins for the Sp1–ZnF plasmid; and E. Weber for the Cathepsin B antibody. Hyman M. Schipper has served as consultant to Osta Biotechnologies, TEVA Neurosciences, and Caprion Pharmaceuticals. He holds stock options in Osta and equity in Molecular Biometrics LLC. Anna-Elina Lehesjoki has served as an independent speaker for the symposium “European Forum Addressing Challenges in Epilepsy Care (FACE)” sponsored by Pfizer Limited. Anna-Elina Lehesjoki is the coordinator of a Finnish research consortium “EPIMEC” on Progressive Myoclonic Epilepsy (EPM1). The consortium receives support from UCB Pharma for the project's clinical part for which another investigator is the primary investigator.
- Correspondence should be addressed to either of the following at their above addresses: Azad Bonni, azad_bonni{at}hms.harvard.edu; or Anna-Elina Lehesjoki, E-mail: anna-elina.lehesjoki{at}helsinki.fi